Literature DB >> 20061919

Elevated myeloid: plasmacytoid dendritic cell ratio associates with early acute cellular rejection in pediatric small bowel transplantation.

Ankit Gupta1, Chethan Ashokkumar, Mylarappa Ningappa, Qing Sun, Brandon W Higgs, Sara Snyder, Matthew Johnson, Adriana Zeevi, Kareem M Abu-Elmagd, Angus W Thomson, George V Mazariegos, Rakesh Sindhi.   

Abstract

BACKGROUND: Acute cellular rejection affects more than 60% of children after small bowel transplantation (SBTx). Dendritic cells (DCs) are potent antigen-presenting cells, modulate immune responses to gut microbes, and may serve as markers of rejection-prone small bowel transplantation (SBTx).
METHODS: Myeloid CD11c DC (MDC), which may have inflammatory functions, and plasmacytoid CD123 DC (PDC), which may have tolerogenic potential, were measured by flow cytometric analysis, longitudinally (pretransplant, and at days 1 to 60, 61 to 200 posttransplant) in 23 children after SBTx. All children received cadaveric allografts with rabbit anti-human thymocyte globulin induction and steroid-free tacrolimus maintenance therapy. Rejectors were those children (n=16), who experienced biopsy-proven acute cellular rejection within 60 days of SBTx.
RESULTS: Of 69 maximum possible observations, 62 were available for analysis. Among rejectors, a significantly higher MDC:PDC ratio (P=0.004) was associated with numerically higher MDC counts and significantly lower PDC frequencies (P=0.017) during the 1- to 60-day time period, compared with nonrejectors. Logistic regression analysis, leave-one-out cross-validation, and receiver operating characteristic analysis revealed that MDC:PDC ratio more than or equal to 1.52 was associated with rejector status with sensitivity/specificity of 86/67% during the 1- to 60-day risk period for early SBTx rejection. Repeated measures analysis showed a significantly higher MDC:PDC ratio (P=0.043, F-test) among rejectors, compared with nonrejectors in cumulative data for pre-SBTx and 1- to 60-day time points. No correlation was seen between DC subsets and tacrolimus blood concentration at any time point.
CONCLUSIONS: We conclude that an elevated MDC:PDC ratio associates with early small bowel allograft rejection and may, therefore, identify at-risk recipients in the clinic.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20061919     DOI: 10.1097/TP.0b013e3181bc5d9e

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

Review 1.  Advances in small bowel transplantation.

Authors:  Alp Gürkan
Journal:  Turk J Surg       Date:  2017-09-01

Review 2.  Tolerogenic dendritic cells and their role in transplantation.

Authors:  Mohamed Ezzelarab; Angus W Thomson
Journal:  Semin Immunol       Date:  2011-07-07       Impact factor: 11.130

3.  Increased expression of peripheral blood leukocyte genes implicate CD14+ tissue macrophages in cellular intestine allograft rejection.

Authors:  Chethan Ashokkumar; Mylarappa Ningappa; Sarangarajan Ranganathan; Brandon W Higgs; Qing Sun; Lori Schmitt; Sara Snyder; Jennifer Dobberstein; Maria Branca; Ronald Jaffe; Adriana Zeevi; Robert Squires; Feras Alissa; Benjamin Shneider; Kyle Soltys; Geoffrey Bond; Kareem Abu-Elmagd; Abhinav Humar; George Mazariegos; Hakon Hakonarson; Rakesh Sindhi
Journal:  Am J Pathol       Date:  2011-08-18       Impact factor: 4.307

4.  Long-Term Signs of T Cell and Myeloid Cell Activation After Intestinal Transplantation With Cellular Rejections Contributing to Further Increase of CD16+ Cell Subsets.

Authors:  Nadja Stobutzki; Stephan Schlickeiser; Mathias Streitz; Katarina Stanko; Kim-Long Truong; Levent Akyuez; Katrin Vogt; Christine Appelt; Andreas Pascher; Olga Blau; Undine A Gerlach; Birgit Sawitzki
Journal:  Front Immunol       Date:  2019-05-07       Impact factor: 7.561

5.  CXCR4 blockade reduces the severity of murine heart allograft rejection by plasmacytoid dendritic cell-mediated immune regulation.

Authors:  Jian Fu; Christian H K Lehmann; Xinning Wang; Mandy Wahlbuhl; Ida Allabauer; Benjamin Wilde; Lukas Amon; Sebastian Dolff; Robert Cesnjevar; Andreas Kribben; Joachim Woelfle; Wolfgang Rascher; Peter F Hoyer; Diana Dudziak; Oliver Witzke; André Hoerning
Journal:  Sci Rep       Date:  2021-12-10       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.